FDA Expands Selzentry Indication, But Ties Use To Screening With "Highly Sensitive" Assay
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for additional indication for newly diagnosed patients cautions about higher virologic failure in treatment-naïve patients receiving maraviroc during the clinical trial.